1421373-65-0 | N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$6.00	$4.00
5mg	95%	in stock	$8.00	$5.00
10mg	95%	in stock	$10.00	$7.00
250mg	95%	in stock	$15.00	$10.00
1g	95%	in stock	$56.00	$39.00
5g	95%	in stock	$185.00	$130.00
25g	95%	in stock	$572.00	$400.00
100g	95%	in stock	$1,535.00	$1,074.00

Description

• Catalog Number: AE35413
• Chemical Name: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
• CAS Number: 1421373-65-0
• Molecular Formula: C28H33N7O2
• Molecular Weight: 499.6073
• MDL Number: MFCD27988062
• SMILES: C=CC(=O)Nc1cc(Nc2nccc(n2)c2cn(c3c2cccc3)C)c(cc1N(CCN(C)C)C)OC

Computed Properties

• Complexity: 752
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 37
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 10
• XLogP3: 3.7

Upstream Synthesis Route

The compound N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide plays a crucial role in chemical synthesis, particularly in the realm of medicinal chemistry. Its unique structure makes it a valuable building block for the creation of novel drug candidates. By incorporating this compound into synthetic pathways, chemists can access a diverse array of potential pharmaceutical agents with enhanced biological activities. Its functional groups and substituents offer strategic points for further derivatization, allowing for the optimization of drug-like properties such as solubility, stability, and target specificity. In the field of drug discovery and development, the versatility of N-[2-[[2-(Dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide empowers researchers to design innovative molecules with improved therapeutic potential.

Literature

• L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20161001

• Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.

  Journal of medicinal chemistry 20160728

• Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.

  Therapeutic advances in respiratory disease 20160401

• Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20160401

• Osimertinib: First Global Approval.

  Drugs 20160201

• Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.

  Journal of hematology & oncology 20160101

• Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

  Journal of structural biology 20151201

• Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

  JAMA oncology 20151001

• Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20150901

• Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.

  The Lancet. Oncology 20150901

• The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC).

  Annals of translational medicine 20150501

• Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.

  Current opinion in oncology 20150301

• Dacomitinib in lung cancer: a 'lost generation' EGFR tyrosine-kinase inhibitor from a bygone era?

  Drug design, development and therapy 20150101

• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  Cancer discovery 20140901

• Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.

  Journal of the National Comprehensive Cancer Network : JNCCN 20130201

• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  The New England journal of medicine 20040520